HK1207067A1 - 3-amido-pyrrolo [3, 4-c] pyrazole-5 (1h, 4h, 6h) carbaldehyde derivatives as inhibitors of protein kinase c c 3--[34-c]-5(1h4h6h) - Google Patents

3-amido-pyrrolo [3, 4-c] pyrazole-5 (1h, 4h, 6h) carbaldehyde derivatives as inhibitors of protein kinase c c 3--[34-c]-5(1h4h6h)

Info

Publication number
HK1207067A1
HK1207067A1 HK15107642.0A HK15107642A HK1207067A1 HK 1207067 A1 HK1207067 A1 HK 1207067A1 HK 15107642 A HK15107642 A HK 15107642A HK 1207067 A1 HK1207067 A1 HK 1207067A1
Authority
HK
Hong Kong
Prior art keywords
1h4h6h
pyrrolo
pyrazole
amido
inhibitors
Prior art date
Application number
HK15107642.0A
Other languages
English (en)
Chinese (zh)
Inventor
‧伯特魯斯
洪玉峰
李輝
‧劉
貫井齊治
滕敏
‧湯普金斯
尹春風
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of HK1207067A1 publication Critical patent/HK1207067A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
HK15107642.0A 2007-04-12 2010-06-09 3-amido-pyrrolo [3, 4-c] pyrazole-5 (1h, 4h, 6h) carbaldehyde derivatives as inhibitors of protein kinase c c 3--[34-c]-5(1h4h6h) HK1207067A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US91146207P 2007-04-12 2007-04-12
US3551908P 2008-03-11 2008-03-11
US4011508P 2008-03-27 2008-03-27

Publications (1)

Publication Number Publication Date
HK1207067A1 true HK1207067A1 (en) 2016-01-22

Family

ID=39764996

Family Applications (2)

Application Number Title Priority Date Filing Date
HK15107643.9A HK1207068A1 (en) 2007-04-12 2010-06-09 3-amido-pyrrolo [3,4-c] pyrazole-5 (1h, 4h, 6h) carbaldehyde derivatives as inhibitors of protein kinase c c 3--[34-c]-5(1h4h6h)
HK15107642.0A HK1207067A1 (en) 2007-04-12 2010-06-09 3-amido-pyrrolo [3, 4-c] pyrazole-5 (1h, 4h, 6h) carbaldehyde derivatives as inhibitors of protein kinase c c 3--[34-c]-5(1h4h6h)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK15107643.9A HK1207068A1 (en) 2007-04-12 2010-06-09 3-amido-pyrrolo [3,4-c] pyrazole-5 (1h, 4h, 6h) carbaldehyde derivatives as inhibitors of protein kinase c c 3--[34-c]-5(1h4h6h)

Country Status (11)

Country Link
US (2) US8114871B2 (de)
EP (1) EP2195321B1 (de)
JP (1) JP5404601B2 (de)
KR (1) KR101113387B1 (de)
CN (3) CN101675052A (de)
AU (1) AU2008237660B2 (de)
CA (1) CA2683695C (de)
HK (2) HK1207068A1 (de)
IL (1) IL201104A (de)
MX (1) MX2009010951A (de)
WO (1) WO2008125945A2 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5404601B2 (ja) 2007-04-12 2014-02-05 ファイザー・インク 新規な３−アミド−ピロロ［３，４−ｃ］ピラゾール−５（１Ｈ，４Ｈ，６Ｈ）カルバルデヒド誘導体
ES2545231T3 (es) 2008-05-28 2015-09-09 Pfizer Inc. Inhibidores de pirazoloespirocetona acetil-CoA carboxilasa
EP2485727A4 (de) * 2009-10-06 2013-05-01 Afraxis Inc Pyrrolopyrazole zur behandlung von zns-erkrankungen
AP3283A (en) 2009-11-10 2015-05-31 Pfizer N1-pyrazolospiroketone acetyl-coa carboxylase inhibitors
US9180127B2 (en) 2009-12-29 2015-11-10 Dana-Farber Cancer Institute, Inc. Type II Raf kinase inhibitors
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
CA2811033C (en) 2010-09-30 2015-10-20 Pfizer Inc. N1-pyrazolospiroketone acetyl-coa carboxylase inhibitors
KR20150006899A (ko) 2010-10-29 2015-01-19 화이자 인코포레이티드 N1/N2-락탐 아세틸-CoA 카복실라아제 억제제
UY33905A (es) 2011-02-11 2012-08-31 Glaxosmithkline Llc Inhibidores de la catepsina c
ME02312B (me) 2011-04-22 2016-06-20 Pfizer DERIVATI PIRAZOLOSPIROKETONA, NAMIJENJENI UPOTREBI KAO INHIBITORI ACETIL-CoA-KARBOKSILAZE
EP2567959B1 (de) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridin-4-carbonsäureamid-derivate als kinaseinhibitoren
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US8846712B2 (en) 2011-09-12 2014-09-30 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2755652B1 (de) * 2011-09-16 2021-06-02 Novartis AG N-substituierte heterocyclische carboxamide
EP2760862B1 (de) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridin-4-carbonsäureamidderivate als kinaseinhibitoren
JP6106685B2 (ja) 2011-11-17 2017-04-05 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド Ｃ−ｊｕｎ−ｎ−末端キナーゼ（ｊｎｋ）の阻害剤
WO2013167403A1 (en) 2012-05-09 2013-11-14 Sanofi Substituted 6-(4-hydroxy-phenyl)-1h-pyrazolo[3,4-b]pyridine derivatives as kinase inhibitors
USRE48175E1 (en) 2012-10-19 2020-08-25 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
EP2919788A4 (de) 2012-11-14 2016-05-25 Univ Johns Hopkins Verfahren und zusammensetzungen zur behandlung von schizophrenie
EP3057955B1 (de) 2013-10-18 2018-04-11 Syros Pharmaceuticals, Inc. Zur behandlung von proliferativen erkrankungen geeignete heteroaromatische verbindungen
WO2015058140A1 (en) 2013-10-18 2015-04-23 Dana-Farber Cancer Institute, Inc. Polycyclic inhibitors of cyclin-dependent kinase 7 (cdk7)
AU2015263884B2 (en) 2014-05-23 2019-11-14 Mingsight Pharmaceuticals, Inc. Treatment of autoimmune disease
KR102575327B1 (ko) 2014-10-31 2023-09-07 유비이 가부시키가이샤 치환 디히드로피롤로피라졸 화합물
BR112017007112A2 (pt) * 2014-11-21 2017-12-26 Lilly Co Eli compostos de 1,2-benzotiazol para o tratamento de distúrbios renais
US10870651B2 (en) 2014-12-23 2020-12-22 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
JP6861166B2 (ja) 2015-03-27 2021-04-21 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド サイクリン依存性キナーゼの阻害剤
JP6787314B2 (ja) * 2015-06-15 2020-11-18 宇部興産株式会社 置換ジヒドロピロロピラゾール誘導体
WO2017044858A2 (en) 2015-09-09 2017-03-16 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
CA3005723A1 (en) 2015-11-20 2017-05-26 Mingsight Pharmaceuticals, Inc. Treatment of autoimmune disease
JP2019524700A (ja) 2016-07-14 2019-09-05 ミングサイト ファーマシューティカルズ，インク． 癌の処置
WO2020100944A1 (ja) 2018-11-14 2020-05-22 宇部興産株式会社 ジヒドロピロロピラゾール誘導体

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4555547B2 (ja) * 2000-08-10 2010-10-06 ファイザー イタリア ソシエタ ア レスポンサビリタ リミタータ キナーゼ阻害剤としての二環式ピラゾール、それらを製造するための方法およびそれらを含む医薬組成物
UA81790C2 (uk) * 2002-12-19 2008-02-11 Фармация Италия С.П.А. Заміщені піролопіразольні похідні як інгібітори кінази
US20070037790A1 (en) * 2003-03-11 2007-02-15 Francesca Abrate Bicyclo-pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
AU2004276341B2 (en) * 2003-09-23 2011-04-14 Vertex Pharmaceuticals Incorporated Pyrazolopyrrole derivatives as protein kinase inhibitors
US8067591B2 (en) * 2005-01-10 2011-11-29 Agouron Pharmaceuticals, Inc. Pyrrolopyrazole, potent kinase inhibitors
JP5404601B2 (ja) 2007-04-12 2014-02-05 ファイザー・インク 新規な３−アミド−ピロロ［３，４−ｃ］ピラゾール−５（１Ｈ，４Ｈ，６Ｈ）カルバルデヒド誘導体

Also Published As

Publication number Publication date
EP2195321B1 (de) 2016-10-19
US20120108588A1 (en) 2012-05-03
CN104356136A (zh) 2015-02-18
WO2008125945A2 (en) 2008-10-23
US20100249128A1 (en) 2010-09-30
JP5404601B2 (ja) 2014-02-05
WO2008125945A3 (en) 2009-03-12
CN101675052A (zh) 2010-03-17
JP2010523643A (ja) 2010-07-15
CA2683695C (en) 2013-06-18
AU2008237660A1 (en) 2008-10-23
CA2683695A1 (en) 2008-10-23
US8114871B2 (en) 2012-02-14
HK1207068A1 (en) 2016-01-22
IL201104A (en) 2017-09-28
KR101113387B1 (ko) 2012-04-23
CN104370914A (zh) 2015-02-25
US8999981B2 (en) 2015-04-07
IL201104A0 (en) 2010-05-17
AU2008237660B2 (en) 2011-12-22
MX2009010951A (es) 2009-10-29
EP2195321A2 (de) 2010-06-16
KR20090130039A (ko) 2009-12-17
CN104370914B (zh) 2018-09-07

Similar Documents

Publication Publication Date Title
HK1207068A1 (en) 3-amido-pyrrolo [3,4-c] pyrazole-5 (1h, 4h, 6h) carbaldehyde derivatives as inhibitors of protein kinase c c 3--[34-c]-5(1h4h6h)
HK1139130A1 (en) 3-amino-pyrrolo[3,4-c]pyrazole-5(1h, 4h, 6h) carbaldehyde derivatives as pkc inhibitors pkc 3--[34-c]-5(1h4h6h)
IL278119B (en) Disubstituted pyrazolo[5.1–a]pyrimidine compounds as trk kinase inhibitors
ZA201002318B (en) Pyrrolo [2,3-d]pyrimidin derivatives as protein kinase b inhibitors
HUS1200009I1 (hu) Pirrolo[2,3-B]piridin származékok, mint protein kináz inhibitorok
ZA201200982B (en) Substituted pyrazolo[1,5-a]pyrimidine compounds as trk kinase inhibitors
EP1973910A4 (de) Pyrrolo[3,2-c]-pyridin-4-on-2-indolinon-proteinkinaseinhibitoren
HK1126758A1 (en) Cyclopenta [d] pyrimidines as akt protein kinase inhibitors
ZA200802690B (en) Thieno[2,3-b]pyridine-5-carbonitriles as protein kinase inhibitors
ZA201105896B (en) [1,2,4] triazolo [1,5-a] pyridines as kinase inhibitors
ZA201000627B (en) 2-(2-oxoindoline-3-ylidene)methyl-5-(2-hydroxy-3-morpholin-4-yl-propyl)-6,7-dihydro-1h-pyrrol[3,2-c]pyridine-4(5h)-one compounds and use as protein kinase inhibitors
ZA200907825B (en) 3-amido-pyrrolo [3, 4-C] pyrazole-5 (1H, 4H, 6H) carbaldehyde derivatives as inhibitors of protein kinase C
IL178688A0 (en) THIENO [3,2-b] PYRIDINE-6-CARBONITRILES AS PROTEIN KINASE INHIBITORS